Cargando…

Does the 21-gene recurrence score have clinical utility in HR+/HER2+ breast cancer?

The 21-gene recurrence score assay has been validated as a predictive biomarker in early-stage HR+ and HER2-breast cancer. It is not indicated for use in HER2+ disease based on national guidelines. In this study, we assessed the value of 21-gene recurrence score (RS), or OncotypeDX (ODX), testing in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bilani, Nadeem, Crowley, Fionnuala, Mohanna, Mohamed, Itani, Mira, Yaghi, Marita, Saravia, Diana, Jabbal, Iktej, Dominguez, Barbara, Liang, Hong, Nahleh, Zeina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9493134/ https://www.ncbi.nlm.nih.gov/pubmed/36137495 http://dx.doi.org/10.1016/j.breast.2022.09.002

Ejemplares similares

Management of HR+/HER2+ lobular breast cancer and trends do not mirror better outcomes
por: Yaghi, Marita, et al.
Publicado: (2022)

Metastasectomy versus radiation of secondary sites in stage IV breast cancer: Analysis from a national cancer registry
por: Bilani, Nadeem, et al.
Publicado: (2021)

Disparities in Metabolic Conditions and Cancer Characteristics among Hispanic Women with Breast Cancer: A Multi-Institutional Study
por: Jabbal, Iktej S., et al.
Publicado: (2022)

Impact of COVID-19 on Cancer-Related Care in the United States: An Overview
por: Jabbal, Iktej Singh, et al.
Publicado: (2023)

Factors Associated with the Decision to Decline Chemotherapy in Metastatic Non-Small Cell Lung Cancer
por: Jabbal, Iktej Singh, et al.
Publicado: (2023)

Triple Negative Breast Cancer: Updates on Classification and Treatment in 2021
por: Bou Zerdan, Maroun, et al.
Publicado: (2022)

Pseudofungi in an Immunocompromised Patient with Breast Cancer and COVID-19
por: Bilani, Nadeem, et al.
Publicado: (2020)

Effect of immunotherapy on overall survival in limited-stage small cell lung carcinoma: a national cancer database analysis
por: Bilani, Nadeem, et al.
Publicado: (2021)

Breast Cancer in the United States: A Cross-Sectional Overview
por: Bilani, Nadeem, et al.
Publicado: (2020)

A Multimodal Approach to Evaluate for Cardiac Metastasis in a Case of Non-Small Cell Lung Cancer
por: Bilani, Nadeem, et al.
Publicado: (2020)

Prognostic and Predictive Value of Circulating and Disseminated Tumor Cells in Breast Cancer: A National Cancer Database (NCDB) Analysis
por: Bilani, Nadeem, et al.
Publicado: (2020)

Thymoma and Myasthenia Gravis: An Examination of a Paraneoplastic Manifestation
por: Itani, Mira, et al.
Publicado: (2023)

Real-world Treatment Patterns and Outcomes in HR+/HER2+ Metastatic Breast Cancer Patients: A National Cancer Database Analysis
por: Statler, Abby B., et al.
Publicado: (2019)

Clinical and Demographic Factors, Treatment Patterns, and Overall Survival Associated With Rare Triple-Negative Breast Carcinomas in the US
por: Elimimian, Elizabeth B., et al.
Publicado: (2021)

Merkel cell carcinoma: Epidemiology, disease presentation, and current clinical practice outcomes
por: Yaghi, Marita, et al.
Publicado: (2022)

Long-Term Effect of a Nonrandomized Psychosocial Mindfulness-Based Intervention in Hispanic/Latina Breast Cancer Survivors
por: Elimimian, Elizabeth, et al.
Publicado: (2020)

Male Breast Cancer: A Comparative Analysis from the National Cancer Database
por: Elimimian, Elizabeth B., et al.
Publicado: (2021)

YAP1 Expression in HR+HER2− Breast Cancer: 21-Gene Recurrence Score Analysis and Public Dataset Validation
por: Park, Inho, et al.
Publicado: (2023)

Endocrine Therapy Plus Anti-HER2 Therapy as Adjuvant Systemic Therapy for Luminal HER2-Positive Breast Cancer: An Analysis of the National Cancer Database
por: Nahleh, Zeina A, et al.
Publicado: (2020)

Application of the 21-Gene Recurrence Score in Patients with Early HR-Positive/HER2-Negative Breast Cancer: Chemotherapy and Survival Rate According to Clinical Risk
por: Bae, Soong June, et al.
Publicado: (2021)

Validation of the GenesWell BCT Score in Young Asian Women With HR+/HER2− Early Breast Cancer
por: Kwon, Mi Jeong, et al.
Publicado: (2021)

Combining TMEM Doorway Score and Mena(Calc) Score Improves the Prediction of Distant Recurrence Risk in HR+/HER2− Breast Cancer Patients
por: Ye, Xianjun, et al.
Publicado: (2022)

Permanent stoma: a quality outcome in treatment of rectal cancer and its impact on length of stay
por: Lemini, Riccardo, et al.
Publicado: (2021)

Evolving perspectives on the treatment of HR+/HER2+ metastatic breast cancer
por: Pegram, Mark, et al.
Publicado: (2023)

A new molecular prognostic score for predicting the risk of distant metastasis in patients with HR+/HER2− early breast cancer
por: Gong, Gyungyub, et al.
Publicado: (2017)

21-Gene Recurrence Assay Associated With Favorable Metabolic Profiles in HR-Positive, HER2-Negative Early-Stage Breast Cancer Patients
por: Zhu, Yifei, et al.
Publicado: (2021)

Controversies and Opportunities in the Clinical Daily Use of the 21-Gene Assay for Prognostication and Prediction of Chemotherapy Benefit in HR+/HER2- Early Breast Cancer
por: Jacobs, Flavia, et al.
Publicado: (2022)

Sacituzumab Govitecan in HR-positive HER2-negative metastatic breast cancer
por: Nardin, Simone, et al.
Publicado: (2023)

Slicer EPA HR.SEH 21 : Commande de mouvement
por: Metral, G
Publicado: (1988)

Rhodococcus equi venous catheter infection: a case report and review of the literature
por: Guerrero, Rosalinda, et al.
Publicado: (2011)

Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer
por: Ditsch, Nina, et al.
Publicado: (2019)

Preferences of Canadian Patients and Physicians for Treatment of HR+/HER2− Advanced Breast Cancer
por: Stellato, Daniel, et al.
Publicado: (2021)

American Society of Clinical Oncology 2021 Podcast: HR+, HER2− Breast Cancer
por: Cheung, Kwok-Leung
Publicado: (2021)

The Synergistic Effects of SHR6390 Combined With Pyrotinib on HER2+/HR+ Breast Cancer
por: Wang, Yukun, et al.
Publicado: (2021)

The Net Promoter Score with Friends and Family Test applied to arthroscopic shoulder surgery
por: Monu, Jabbal, et al.
Publicado: (2023)

A novel treatment strategy of HER2-targeted therapy in combination with Everolimus for HR+/HER2- advanced breast cancer patients with HER2 mutations
por: Ma, Jing, et al.
Publicado: (2022)

Prostate Cancer and Aspirin Use: Synopsis of the Proposed Molecular Mechanisms
por: Bilani, Nadeem, et al.
Publicado: (2017)

How to reduce your cancer risk: mechanisms and myths
por: Nahleh, Zeina, et al.
Publicado: (2011)

Prognostic impact of HER2-low positivity in patients with HR-positive, HER2-negative, node-positive early breast cancer
por: Shikata, Shohei, et al.
Publicado: (2023)

Targeted Neoadjuvant Therapies in HR+/HER2−Breast Cancers: Challenges for Improving pCR
por: Dey, Nandini, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_h5q4ulpukvc4vei3u91bn1360t